Post Marketing Surveillance Study to Observe Safety and Effectiveness of CRYSVITA® in S. Korean Patients

NCT06202027 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-08-29

No results posted yet for this study

Summary

The objective of this post-marketing surveillance (PMS) study is to assess the safety and effectiveness of CRYSVITA injection 10, 20, and 30mg, equivalent to in routine clinical settings

Conditions

  • FGF23-related Hypophosphataemic Rickets and Osteomalacia

Interventions

DRUG

FGF23-related hypophosphataemic rickets and osteomalacia

FGF23-related hypophosphataemic rickets and osteomalacia

Sponsors & Collaborators

  • Kyowa Kirin Korea Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • HaeMi Park · Kyowa Kirin Korea Co., Ltd.

Eligibility

Min Age
1 Day
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-11
Primary Completion
2031-06-16
Completion
2031-07-16

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06202027 on ClinicalTrials.gov